Nov 13 (Reuters) – Danish vaccine maker Bavarian Nordic reported higher than expected revenue for the third quarter on Friday, boosted by a continued strong performance in its travel health business.
Bavarian’s outlook increasingly hinges on whether strong rabies demand proves durable and whether newer products such as Vimkunya can offset volatility in the preparedness-vaccine business.
• Q3 revenue came to 1.81 billion Danish crowns ($267.81 million) against year-earlier 1.80 billion
• It beat analysts’ average estimate of 1.69 billion in a company-provided consensus
• Bavarian reiterated the full-year guidance it upgraded in October, driven by higher US rabies vaccine sales
• Travel health revenue rose 22% to 1.14 billion crowns against company-provided consensus of 1.02 billion, driven by continued strong RabAvert/Rabipur sales and supported by the continued launch of Vimkunya
($1 = 6.7585 Danish crowns)
(Reporting by Elviira Luoma, editing by Matt Scuffham)
